tbuckley/cabot-search huggingface dataset:
Heat-labile<i>Escherichia coli</i>toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination
Authors: C. R. Cabauatan, R. Campana, K. Niespodziana, C. Reinisch, U. Lundberg, A. Meinke, R. Henning, A. Neubauer, R. Valenta
Journal: Allergy (2016)

Epicutaneous allergen-specific immunotherapy (EPIT) is proposed as an alternative route for allergen-specific immunotherapy (AIT). The induction of allergen-specific blocking IgG antibodies represents an important mechanism underlying AIT, but has not been investigated for EPIT. Here, we compared the induction of allergen-specific blocking IgG in outbred guinea pigs which had been immunized with recombinant birch pollen allergen Bet v 1 using patch delivery system (PDS) with or without heat-labile toxin (LT) from Escherichia coli or subcutaneously with aluminum hydroxide (Alum)-adsorbed rBet v 1. Only subcutaneous immunization with Alum-adsorbed rBet v 1 and epicutaneous administration of rBet v 1 with PDS in combination with LT from E. coli induced allergen-specific IgG antibodies blocking allergic patients' IgE, but not immunization with rBet v 1 via PDS alone. Our results suggest that patch vaccination with rBet v 1 in combination with LT may be a promising strategy for allergen-specific immunotherapy against birch pollen allergy.
Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
Authors: Anette Sommer, Charlotte Kopitz, Christoph A. Schatz, Carl F. Nising, Christoph Mahlert, Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Stefanie Hammer, Simone Greven, Joachim Schuhmacher, Manuela Braun, Ruprecht Zierz, Sabine Wittemer-Rump, Axel Harrenga, Frank Dittmer, Frank Reetz, Heiner Apeler, Rolf Jautelat, Hung Huynh, Karl Ziegelbauer, Bertolt Kreft
Journal: Cancer Research (2016)

The fibroblast growth factor receptor FGFR2 is overexpressed in a variety of solid tumors, including breast, gastric, and ovarian tumors, where it offers a potential therapeutic target. In this study, we present evidence of the preclinical efficacy of BAY 1187982, a novel antibody-drug conjugate (ADC). It consists of a fully human FGFR2 monoclonal antibody (mAb BAY 1179470), which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc, conjugated through a noncleavable linker to a novel derivative of the microtubule-disrupting cytotoxic drug auristatin (FGFR2-ADC). In FGFR2-expressing cancer cell lines, this FGFR2-ADC exhibited potency in the low nanomolar to subnanomolar range and was more than 100-fold selective against FGFR2-negative cell lines. High expression levels of FGFR2 in cells correlated with efficient internalization, efficacy, and cytotoxic effects in vitro Pharmacokinetic analyses in mice bearing FGFR2-positive NCI-H716 tumors indicated that the toxophore metabolite of FGFR2-ADC was enriched more than 30-fold in tumors compared with healthy tissues. Efficacy studies demonstrated that FGFR2-ADC treatment leads to a significant tumor growth inhibition or tumor regression of cell line-based or patient-derived xenograft models of human gastric or breast cancer. Furthermore, FGFR2 amplification or mRNA overexpression predicted high efficacy in both of these types of in vivo model systems. Taken together, our results strongly support the clinical evaluation of BAY 1187982 in cancer patients and a phase I study (NCT02368951) has been initiated. Cancer Res; 76(21); 6331-9. ©2016 AACR.
Case 30-1969
Authors: Gerald S. Foster, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of Case First admission. A fifty-eight-year-old woman was admitted to the hospital because of jaundice and abdominal swelling.She had been in good health until six months previously, when epigastric pain developed. An upper gastrointestinal series was said to show a small peptic ulcer and a hiatus hernia; a barium-enema examination was interpreted as negative. With a bland diet and anticholinergic medication the pain subsided. One month before entry she became depressed, listless, anorectic and easily fatigued. She noticed lightening of the color of the stools, and two weeks before entry yellow discoloration of the skin appeared. A week . . .
Long-term Recurrence-free Survival After Standard Endoscopic Resection Versus Surgical Resection of Submucosal Invasive Colorectal Cancer: A Population-based Study
Authors: Tim D.G. Belderbos, Felice N. van Erning, Ignace H.J.T. de Hingh, Martijn G.H. van Oijen, Valery E.P.P. Lemmens, Peter D. Siersema
Journal: Clinical Gastroenterology and Hepatology (2016)
Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models
Authors: Cory Mavis, Juan Gu, Joseph Skitzki, Francisco Hernandez, Myron S. Czuczman
Journal: Blood (2013)
Prognostic Indices in Older DLBCL Patients Receiving R-CHOP: An Analysis of the U.S. Intergroup Study (E4494, CALGB 9793).
Authors: R.H. Advani, H. Chen, T.M. Habermann, V.A. Morrison, E. Weller, R.I. Fisher, B.A. Peterson, R.D. Gascoyne, S.J. Horning
Journal: Blood (2006)
Assessing severe asthma
Authors: Douglas S. Robinson
Journal: European Respiratory Journal (2016)

In the current issue of the European Respiratory Journal , van der Meer et al. [1] describe data from a 1 day assessment of difficult to treat asthma at their specialist centre in the Netherlands. They conclude that the structured assessment identified misdiagnosis, and improved asthma control and quality of life. Structured assessment of patients identifies asthma misdiagnosis, and improves asthma control and quality of life <http://ow.ly/Rx3p3017DTx>
Geoffrey Donald Wilson
Authors: Giles Wilson
Journal: BMJ (2016)

Geoffrey Donald Wilson was the youngest of seven children to Alice Mabel and John George Wilson. His mother was a journalist, and his father worked on the railways. He was born in the small village of Wavendon in Bedfordshire, near what is now Milton Keynes. At that time the family home had no electricity, TV, radio, phone, running water, or sewer system.

Geoffrey won a scholarship to Bedford Modern School, where he studied ancient history, English, and Latin. He enrolled with the Royal Air Force in 1940. He was not able to become a pilot because of a medical condition affecting his heart, …
Final results of a phase II trial [PARC-Study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine
Authors: M. Munter, C. Timke, A. Abdollahi, H. Friess, D. Jaeger, S. Heeger, M. Buchler, J. Debus, P. Huber, R. Krempien
Journal: Journal of Clinical Oncology (2008)

4613 Background: To evaluate the feasibility and efficacy of trimodal therapy using cetuximab in combination with IMRT and gemcitabine in locally advanced pancreatic cancer. Methods: In this randomized Phase II trial (planned sample size 66 pts), chemotherapy-naive pts. with primary inoperable locally advanced pancreatic cancer were eligible. For both arms initial treatment consisted of radiotherapy, gemcitabine weekly (300 mg/m2), and cetuximab weekly (loading dose 400 mg/m2 day 1, concomitant with RT 250 mg/m2). After trimodal therapy pts in arm A received gemcitabine weekly (1,000 mg/m2) over 4 weeks, and pts in study arm B received gemcitabine weekly (1,000 mg/m2) over 4 weeks and cetuximab (250 mg/m2) weekly over 12 weeks. IMRT was delivered using an integrated boost concept (54 Gy GTV, 45 Gy CTV) over 5 weeks. Response evaluation (CT) followed at week 12 and every 3 months. All pts were treated with gemcitabine weekly (1,000 mg/m2) over 3 months after end of study. Primary study end point was response; secondary end points were overall survival, secondary resection rate and adverse events. Results: Between 2/05 and 4/07 68 pts were enrolled (characteristics: pancreatic adenocarcinoma c2 T4 N1 68/68, median age = 62 (range 48–79); M/F = 38/30; ECOG PS 0/1/2 = 17/45/6). Complete response in 1/68, partial response in 23/68, no change in 41/68 and progressive disease in 3/68 pts was found according the RECIST criteria in the CT controls. Median follow-up at present is 11 months, 1-and 2- year survival is 61% and 20 %, respectively, median survival is 15 months. No statistical significance was reached concerning overall survival between the treatment arms. 40/68 pts were amenable for secondary potentially curative resection. 14 pts could be resected. Overall toxicity was acceptable and consistent with the profiles of the individual agents. Conclusions: Trimodal therapy for primary inoperable locally advanced inoperable pancreatic carcinoma is safe and resulted in excellent local control and overall survival. No statistical significant difference between the two treatment arms could be found. Distant metastases were the main cause of failure. No significant financial relationships to disclose.
Ideal (IBW) Rather Than Actual (ABW) Body Weight Should Be Used To Calculate Cell Dose in Allogeneic HSCT.
Authors: Seema Singhal, A. Evens, O. Frankfurt, L. Gordon, R. Meagher, M. Tallman, S. Williams, J. Winter, D. Grinblatt, L. Kaminer, J. Mehta
Journal: Blood (2005)
Violent Offending and Suicidal Behavior Have Common Familial Risk Factors
Authors: David A. Brent, Nadine M. Melhem, Holly C. Wilcox
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Modeling Antileukemic Adoptive Immunotherapy In Mouse-Humans Chimeras To Identify Novel Mechanisms Of Cancer Immunoediting
Authors: Giacomo Oliveira, Cristina Toffalori, Jose Manuel Garcia-Manteiga, Barbara Camisa, Lara Crucitti, Dejan Lazarevic, Jacopo Peccatori, Massimo Bernardi, Claudio Bordignon, Attilio Bondanza, Elia Stupka, Fabio Ciceri, Katharina Fleischhauer, Chiara Bonini, Luca Vago
Journal: Blood (2013)
Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma.
Authors: Ragini Reiney Kudchadkar, Donna Gallenstein, Alberto J Martinez, Bin Yu, Jeffrey S. Weber
Journal: Journal of Clinical Oncology (2012)

8582 Background: BMS-936558, a fully human IgG4 anti-PD-1 antibody, has shown clinical activity in melanoma and renal cancer. Methods: 30 HLA A*0201 positive patients with unresectable, previously treated stage IV melanoma received MART-1/gp100/NY-ESO-1 peptides with adjuvant Montanide ISA 51 injected subcutaneously with BMS-936558 at 1, 3 or 10 mg/kg intravenously every 2 weeks for 24 weeks, followed by BMS-936558 alone every 3 months. No patient had prior ipilimumab. Endpoints were toxicity, correlative studies of immunity measured by ELISPOT and T-cell phenotype assays, and response by RECIST. Results: Median age was 62, with 14 men and 16 women. 73% of patients had M1c disease. One patient had dose limiting optic neuritis; one patient had dose limiting grade 3 interstitial pneumonitis. Of 10 patients at 1 mg/kg, 2 had confirmed partial responses (PR), both one year from initiation of study. 13 patients were treated at the 3 mg/kg cohort; 3 patients did not complete more than 3 doses secondary to progressive disease and one withdrew consent. Of 12 evaluable patients, 3 had confirmed PRs and 2 unconfirmed PRs. In the 10 mg/kg cohort, thus far 6 patients completed one cycle with 2 unconfirmed PRs and one patient stable. Only 2 of the 9 responders after one cycle have progressed with a median follow-up of 7 months. 2/6 patients failing BMS-936558 responded to ipilimumab. At week 12, patients in all cohorts had decreased PD-1 on CD4 and CD8 T-cells (p&lt;0.0001), increased CD4 CTLA-4 levels (p=0.01) and dose related decreases in CD8 T-cells whereas CD4 T-cells increased (both p&lt;0.05). ELISPOT assays showed that patients at all doses had no increased responses in fresh PBMC to MART-1/gp100, but showed dose related decreased responses to viral (CMV, EBV, FLU) peptides over time (p=0.04). Conclusions: BMS-936558 in combination with a peptide vaccine is well tolerated at 1 and 3mg/kg. Accural to the 10mg/kg cohort is on-going. Responses have been observed at all dose levels. PD-1 levels on T-cells decreased, and CTLA-4 levels increased in CD4 T cells in all cohorts. There was a dose-related decrease in CD8 T-cells and in viral-specific T-cells. Further study of BM-936558 is warranted to determine its optimal dose.
Risk of Hypoglycemia With Antihypertensive Medication-Reply
Authors: John M. Westfall
Journal: JAMA (1997)

<h3>In Reply</h3> —We appreciate the interest in and comments about our recent article describing the personal use of drug samples by physicians and office staff. We are not surprised at the number or variety of responses or by the depth of emotion evoked. We applaud Dr Margolis' and Dr Rosner's reiteration of the ethical concerns raised in our article. We agree that there is a multitude of ethical dilemmas facing health care. However, as evidenced by the range of letters above, we believe the issues surrounding use of drug samples are important and deserve wide discussion and debate. We appreciate Rosner's broader discussion of other gifts from the pharmaceutical industry and feel this also deserves continued discussion. Dr Reynolds appears to have misunderstood our calculations. We reported a total of about $10 000 worth of drug samples taken for personal or family use. We attempted to minimize the discussion about dollar values
Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
Authors: David Samuel diCapua Siegel, Laura McBride, Elizabeth Bilotti, Linda Schmidt, Zhijie Gao, Madiha Tufail, Nikoletta Lendvai, Ann McNeill, Kristen Donadio, Karly Olivo, Urzula Bednarz, Thorsten Graef, David H. Vesole
Journal: Blood (2010)
Diversity of T H cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania
Authors: Xiangdong Wang, Nan Zhang, Mingyu Bo, Gabriele Holtappels, Ming Zheng, Hongfei Lou, Hong Wang, Luo Zhang, Claus Bachert
Journal: Journal of Allergy and Clinical Immunology (2016)

To date, no study has evaluated the diversity of TH cell cytokine patterns of patients with chronic rhinosinusitis (CRS) among centers in different continents using identical methods.We sought to assess TH cytokine profiles in patients with CRS from Europe, Asia, and Australia.Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP; n = 435) and control subjects (n = 138) were recruited from centers in Adelaide, Benelux, Berlin, Beijing, Chengdu, and Tochigi. Nasal mucosal concentrations of TH2, TH17, and TH1 cytokines; eosinophilic cationic protein (ECP); myeloperoxidase (MPO); IL-8; and tissue total and Staphylococcus aureus enterotoxin (SE)-specific IgE were measured by using identical tools.Combinations of TH1/TH2/TH17 cytokine profiles in patients with CRSwNP varied considerably between regions. CRSwNP tissues from patients from Benelux, Berlin, Adelaide, and Tochigi were TH2 biased, whereas those from Beijing mainly demonstrated TH2/TH1/TH17 mixed patterns, and patients from Chengdu showed an even lower TH2 expression. Concentrations of IL-8 and tissue total IgE in patients with CRSwNP were significantly higher than those in control subjects in all regions. More than 50% of patients with CRSwNP in Benelux, Berlin, Adelaide, and Tochigi showed a predominantly eosinophilic endotype compared with less than 30% of patients in Beijing and Chengdu. SE-specific IgE was found in significantly greater numbers in patients with CRSwNP from Benelux, Adelaide, and Tochigi and significantly lower numbers in patients from Beijing and Chengdu. Moreover, the TH1/TH2/TH17 cytokine profiles in patients with CRSsNP showed diversity among the 6 regions.TH cytokine levels, eosinophilic/neutrophilic patterns, and SE-specific IgE expressions show extreme diversity among patients with CRS from Europe, Asia, and Oceania.
The Population Benefit of Radiotherapy for Malignant Brain Tumors: Local Control and Survival Estimates for Guideline-Based Use
Authors: Timothy Paul Hanna, Geoffrey Paul Delaney, Michael Bernard Barton
Journal: Journal of the National Comprehensive Cancer Network (2016)

Objective: To estimate the population benefit of radiotherapy (RT) for primary malignant brain tumors if evidence-based guidelines were routinely followed. Methods: This study investigated 5-year local control (LC) and 2- and 5-year overall survival (OS) benefits. RT benefit was the absolute proportional benefit of RT alone over no RT for radical indications, and over surgery alone for adjuvant indications. Chemoradiotherapy (CRT) benefit was the absolute incremental benefit of concurrent chemotherapy and RT over RT alone. Decision tree models were adapted to define the incidence of each indication. Citation databases were systematically queried for the highest level of evidence defining indication benefits. Meta-analysis was performed if there were multiple sources of the same evidence level, and deterministic and probabilistic sensitivity analysis was also performed. Results: Among all patients with malignant brain tumors, 82% had indications for curative- or adjuvant-intent RT. The magnitude of benefit was based on level I or II evidence in 44% of all patients. A total of 25 relevant studies were used to quantify indication benefits. All RT benefit included in the model was irreplaceable. For malignant brain tumors, the estimated population benefit for RT alone was 9% for 5-year LC (95% CI, 7%–10%), 9% for 2-year OS (95% CI, 8%–11%), and 5% for 5-year OS (95% CI, 4%–5%). The incremental benefit of CRT was 1% for 5-year LC (95% CI, 0%–2%), 7% for 2-year OS (95% CI, 4%–11%), and 3% for 5-year OS (95% CI, 1%–5%). The model was robust in sensitivity analysis. Conclusions: When optimally used, RT provides an important benefit for many patients with malignant brain tumors. The model provided a robust means for estimating the magnitude of this benefit.
In severe aortic stenosis, TAVR was noninferior to conventional surgery for death or disabling stroke at 2 years
Authors: Kim A. Eagle, Richard L. Weinberg
Journal: Annals of Internal Medicine (2016)

ACP Journal Club16 August 2016In severe aortic stenosis, TAVR was noninferior to conventional surgery for death or disabling stroke at 2 yearsKim A. Eagle, MD, Richard L. Weinberg, MD, PhDKim A. Eagle, MDUniversity of Michigan, Ann Arbor, Michigan, USA (K.A.E., R.L.W.)Search for more papers by this author, Richard L. Weinberg, MD, PhDUniversity of Michigan, Ann Arbor, Michigan, USA (K.A.E., R.L.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-165-4-021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLeon MB, Smith CR, Mack MJ, et al; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-20. https://pubmed.ncbi.nlm.nih.gov/27040324Clinical Impact RatingsGIM/FP/GP: Cardiology: References1 Smith CR, Leon MB, Mack MJ, et al; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-98. [PMID: 21639811] Google Scholar2 Adams DH, Popma JJ, Reardon MJ, et al; U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790-8. [PMID: 24678937] Google Scholar3 Mack MJ, Leon MB, Smith CR, et al; PARTNER 1 trial investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385;2477-84. [PMID: 25788234] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Michigan, Ann Arbor, Michigan, USA (K.A.E., R.L.W.)This article was published at Annals.org on 2 August 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 August 2016Volume 165, Issue 4Page: JC21KeywordsAcute renal failureAortic valve replacementAtrial fibrillationHazard ratioHemorrhageMyocardial infarctionStenosisStrokeSurgeonsSurgery ePublished: 16 August 2016 Issue Published: 16 August 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Circulating tumor cells (CTC) in metastatic hepatocellular carcinoma (HCC): Comparison to control patients with nonmalignant liver diseases (NMLD) and exploratory characterization by next generation sequencing (NGS).
Authors: Robin Katie Kelley, Mark Jesus Mendoza Magbanua, Timothy M Butler, Nikoletta Sidiropoulos, Jimmy Hwang, Kimberley Evason, Bilal Hameed, Elizabeth M Wayne, Francis Y Yao, Iche Siah, John W. Park, Alan Paul Venook, Eric Andrew Collisson
Journal: Journal of Clinical Oncology (2013)

207 Background: Noninvasive biomarkers are urgently needed to improve diagnosis, prognosis, and molecular characterization in HCC. Detection of CTC by EpCAM-enrichment methods is associated with poor outcomes in other tumors. Approximately 35% of HCC are EpCAM+. We hypothesized that CTC are detectable in a subset of metastatic HCC but not in NMLD and that CTC DNA might serve as a source of tumor DNA for biomarker detection and discovery. Methods: Whole blood was obtained from (1) patients with metastatic HCC and (2) NMLD controls. CTC were enumerated using CellSearch by blinded investigators. If &gt; 10 CTC/7.5 mL, immunomagnetic enrichment for EpCAM followed by fluorescence-activated cell sorting (FACS) was also performed to collect highly purified CTC for whole genome amplification (WGA) by GenomePlex WGA4 kit. NGS using 46-gene AmpliSeq Cancer Panel (Ion Torrent) was performed on DNA from CTC, formalin-fixed paraffin embedded tumor (FFPE), and peripheral blood mononuclear cells (PBMC) if available. Results: 20 HCC and 10 NMLD were enrolled. FFPE was available in 7 HCC. In HCC cohort, median alpha-fetoprotein (AFP) was 492 ng/mL (range: 3.8-587,134) and vascular invasion (VI) was present in 13/20 (65%). CTC ≥ 3/7.5 mL were detected in 6/20 (30%, 95% CI: 0.08, 0.52) HCC and 0/9 (95% CI: 0, 0) eligible NMLD (p=0.07). One NMLD had CTC &gt; 3/7.5 mL but was found to have HCC on surveillance ultrasound and excluded. CTC ≥ 3/7.5 mL were associated with AFP ≥ 400 (p=0.01) and VI (p=0.05) by Fisher’s exact test. NGS identified mutations listed in COSMIC in the majority including TP53 and CTNNB1. Variants appeared more frequent in CTC than FFPE in this small sample. Coverage was significantly lower in CTC than FFPE (coverage 20x mean 50% vs 93%, p &lt; 0.02 by unpaired t-test). Conclusions: CTC are a promising biomarker in metastatic HCC and merit further study, including non-EpCAM methods. CTC were associated with AFP and VI. NGS of CTC WGA DNA is feasible and identified characteristic mutations but was limited by coverage bias. Updated NGS findings including 5 cases with paired CTC, FFPE, and/or PBMC will be presented.